Traws Pharma share price logo

Traws Pharma

NASDAQ: TRAW

$0.54

-0.03

(-5.43%)

as on

Traws Pharma Stock Performance

as on August 18, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $0.53
    $0.56
    downward going graph

    1.85%

    Downside

    3.70%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.43
    $3.27
    downward going graph

    20.35%

    Downside

    504.63%

    Upside

    downward going graph

Traws Pharma share price movements today

Previous Close
$0.57
Open
$0.56
Volume
390.1K
Market Cap
$8.7M
Day's Low - High
$0.53 - $0.56
52 Week Low - High
$0.43 - $3.27

Traws Pharma Historical Returns

1 Month Return
-14.9 %
3 Month Return
-69.63 %
1 Year Return
-62.19 %
3 Year Return
0 %
5 Year Return
0 %

Traws Pharma Stock Fundamentals & Key Indicators

Check Traws Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$8.7M

EPS (TTM)

-0.98

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.69

Industry PE ratio

-1.5966015625

PEG Ratio

0.00792679856274938

EBITDA

-15.5M

Revenue (TTM)

2.7M

Profit Margin

0.00%

Return On Equity TTM

489.90%

Traws Pharma Stock Valuation

Track how Traws Pharma P/E has moved over time to understand its valuation trends.

Traws Pharma in the last 5 years

  • Overview

  • Trends

Lowest (-2.66x)

December 31, 2021

Industry (-1.60x)

March 31, 2026

Today (1.36x)

March 31, 2026

Highest (1.36x)

March 31, 2026

LowHigh

Today’s Price to Earnings Ratio: 1.36x

Traws Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Traws Pharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Traws Pharma image
Traws Pharma
BUY$8.7MNA-0.690.00%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Traws Pharma Stock including INR - Dollar returns

The Traws Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Traws Pharma investment value today

Current value as on today

₹39,153

Returns

-₹60,847

(-60.85%)

Returns from Traws Pharma Stock

-₹64,238 (-64.24%)

Dollar Impact

₹3,392 (+3.39%)

Analyst Recommendation on Traws Pharma Stock

Based on 2 analysts

BUY

0.00%

Buy

100.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Traws Pharma. Average target price of $1

Traws Pharma Share Price Target

Get share price movements and forecasts by analysts on Traws Pharma.

What analysts predicted

46%UPSIDE

Target Price

$1

Current Price

$0.54

Analyzed by

2 Analysts

Target

$1.00

Traws Pharma target price $1, a slight upside of 46% compared to current price of $0.54. According to 2 analysts rating.

Indian Investors' Interest in Traws Pharma Stock

Search interest for Traws Pharma Stock has decreased by -10% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-10% versus previous 30 day period

Traws Pharma Quarterly Profit & Loss

All numbers in Millions USD

Dec 2021
Jun 2022
Dec 2022
Jun 2023
Mar 2024
Jun 2024
Dec 2024
Jun 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
0
0
0
0
2
-
-
Gross Profit
0
0
0
0
0
0
0
2
-
-
Operating Income
-7
-8
-11
-10
-9
-5
-8
-1
-7
-6
EBITDA
-7
-8
-11
-10
-9
-5
-8
-1
-7
-6
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-7
-8
-10
-10
-8
-4
-8
0
-7
-7
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-7
-8
-10
-10
-8
-4
-8
0
-7
-7
Net Profit Margin
96.46%
100.00%
96.46%
100.00%
96.46%
100.00%
96.49%
100.00%
0.00%
0.00%

Traws Pharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Mar 2024
Dec 2024
Mar 2026
Total Revenue
0
1
2
0
0
0
0
0
2
Gross Profit
-
-
2
0
0
0
0
0
2
Operating Income
-25
-23
-21
-24
-16
-19
-20
-49
-17
EBITDA
-23
-20
-21
-24
-16
-19
-20
-166
-17
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-24
-20
-21
-25
-16
-18
-18
-166
9
Income Tax Expense
0
0
0
0
-
-
-
-
-
Net Income
-24
-20
-21
-25
-16
-18
-18
-54
9
Net Profit Margin
0.00%
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%
94.69%
100.00%

Traws Pharma Quarterly Cash Flow

All numbers in Millions USD

Dec 2021
Jun 2022
Dec 2022
Jun 2023
Mar 2024
Jun 2024
Dec 2024
Jun 2025
Mar 2026
Jun 2026
Net Income
-3
-4
-5
-4
-4
-123
81
0
-7
-7
Operating Cash Flow
-4
-4
-3
-4
-4
-9
-4
-5
-2
-2
Investing Cash Flow
-
-
-
-
-
-3
-
-
-
-
Financing Cash Flow
0
-
-
-
-
13
19
3
0
1
Change in Cash
-4
-4
-3
-4
-4
0
15
-2
-2
0

Traws Pharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Mar 2024
Dec 2024
Mar 2026
Net Income
-24
-20
-21
-25
-16
-18
-18
-166
9
Operating Cash Flow
-23
-22
-20
-23
-19
-16
-17
-29
-18
Investing Cash Flow
-
-
0
0
-
-
0
-3
-2
Financing Cash Flow
6
35
26
19
55
-
-
33
3
Change in Cash
-17
12
5
-3
36
-16
-17
0
-17

Mutual Funds that own Traws Pharma Stock

Check out the Mutual Funds with significant holdings in Traws Pharma.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.376659%
57359
VANGUARD INDEX FUNDS
0.362436%
55193

Global Institutional Holdings in Traws Pharma

Funds
Holdings
Vanguard
2.17%

Traws Pharma News & Key Events

  • img

    Today's Timeline - 13 November

    Thu, 06:03 PM

    -

    Traws Pharma reports Q3 2025 results, highlighting revenue growth and advancements in clinical programs for respiratory viral diseases.

Insights on Traws Pharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -7.44M → -7.10M (in $), with an average increase of 4.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 460.9% return, outperforming this stock by 523.1%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 2.73M → 57.0K (in $), with an average decrease of 97.9% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, TRAW stock has moved down by -69.6%

About Traws Pharma

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
OrganisationTraws Pharma
Headquarters12 Penns Trail, Newtown, PA, United States, 18940
IndustryBiotechnology
CEODr. Iain D. Dukes DPHIL, M.A., Ph.D.
E-voting on sharesClick here to vote

Key Management of Traws Pharma

Name

Title

Dr. Robert R. Redfield M.D.

Chief Medical Officer

Dr. Iain D. Dukes DPHIL, M.A., Ph.D.

CEO, Secretary & Director

Dr. Nikolay Savchuk Ph.D.

COO & Director

Dr. Charles David Pauza Ph.D.

Chief Scientific Officer of Virology

Mr. Charles Parker

Chief Financial Officer

Dr. Victor Mandia Moyo M.D.

Chief Medical Officer of Oncology

FAQs

What is Traws Pharma share price today?

Traws Pharma share price today is $0.54 as on at the close of the market. Traws Pharma share today touched a day high of $0.56 and a low of $0.53.

What is the 52 week high and 52 week low for Traws Pharma share?

Traws Pharma share touched a 52 week high of $3.27 on and a 52 week low of $0.43 on . Traws Pharma stock price today i.e. is closed at $0.54,which is 83.46% down from its 52 week high and 25.55% up from its 52 week low.

What is Traws Pharma's market capitalisation today?

Traws Pharma market capitalisation is $0.00T as on .

How to invest in Traws Pharma Stock (TRAW) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Traws Pharma on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Traws Pharma Shares that will get you 2.7778 shares as per Traws Pharma share price of $0.54 per share as on August 18, 2026 at 1:29 am IST.

What is the minimum amount required to buy Traws Pharma Stock (TRAW) from India?

Indian investors can start investing in Traws Pharma (TRAW) shares with as little as ₹95.592 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.92 in Traws Pharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Traws Pharma share’s latest price of $0.54 as on August 18, 2026 at 1:29 am IST, you will get 18.5185 shares of Traws Pharma. Learn more about fractional shares .